Hello, Fool! | Login | Signup | My Fool
Oct 6, 2008 10:24 PM ET | Feedback | Site Changes | Help
Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.
View Ticker Page (CRME)
Results 1 - 10 of 20 : 12
Recs
dividendsrg8t85 (51.10) Submitted: 1/08/08 3:56 PM : Start Price: $8.50 CRME Score: 4.13
Vernakalant (IV) is almost a lock for FDA approval. It is the first drug of its type to hit the market in eight years. The death in the study had NOTHING to do with the drug and if people, including analysts, would read the ...
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
snark43 (< 20) Submitted: 12/08/07 5:28 AM : Start Price: $9.10 CRME Score: -5.17
A one drug company with a negative FDA panel recomendation = NO approval and a plummeting priceThe Phase III had a fatal incident and and was not even conducted with the most at risk (and most probable potential customer). In light of the FDA's rec...
WhenOppsKnock (< 20) Submitted: 4/16/08 10:22 PM : Start Price: $7.10 CRME Score: 18.45
The IV version of its anti-fib heart drug, Kynapid (vernakalant hydrochloride), was recommended for approval with a 6-2 vote by an FDA advisory committee in December 2007. No action letter was delivered by the FDA to either Cardiome or its partner, ...
TMFBreakerJava (99.08) Submitted: 3/17/08 9:51 AM : Start Price: $8.55 CRME Score: -3.09
Phase II results released today have shown that their treatment for atrial fibrillation is effective. Lots of upside from here.
aminvestments (75.55) Submitted: 3/18/08 3:26 AM : Start Price: $8.30 CRME Score: 1.39
baby boomers ageing
pops83 (94.10) Submitted: 4/02/08 2:22 AM : Start Price: $8.34 CRME Score: 4.88
Vernakalant hydrochloride (KYNAPID) is the first new drug for use in conversion of Afib in 8 years. With a conversion time of +/- 11 minutes, I can see this being the first line I.V. drug used for new onset Afib patients in the ER setting. While ther...
biovestor (< 20) Submitted: 6/30/08 10:26 AM : Start Price: $8.63 CRME Score: -3.35
Still waiting on FDA ruling for Kynapid, which should be approved plus oral form of the drug with more commercial potential and continued clinical development to move the shares higher.
TMFHelical (99.55) Submitted: 8/11/08 2:59 PM : Start Price: $9.37 CRME Score: -7.94
Dreaded (and not altogether unexpected) approvable letter came out today and the stock plunged. This is a one trick pony ( actually one pony - two tricks) but it should eventually get approved (or bought outright).
zzlangerhans (98.67) Submitted: 10/04/08 5:53 PM : Start Price: $7.78 CRME Score: -2.62
Despite some obvious speed bumps, I think Cardiome remains significantly undervalued given the prospects for both IV and oral vernakalant. While the process is certainly frustrating for impatient investors, the eventual payoff is likely to be very hi...
steelpoker (< 20) Submitted: 2/25/08 7:42 PM : Start Price: $7.37 CRME Score: 15.28
Going to get approved... Good long-term prospects. Got 30% pre-caps, but still a good investment.
Terms & Conditions
RSS Headlines
Fool UK